Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.38 |
| ▸ | CNR1 | P21554 | 5/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.35 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14053290 | 0.90 | CNR1 (0.39) | CNR1RORCYTHDC1 | |
| SCHEMBL15520182 | 0.89 | PPARG (0.35) | PPARGPPARDPSEN1PSEN2APH1B | |
| SCHEMBL2279719 | 0.87 | TRPM8 (0.43) | TRPM8RORC | |
| SCHEMBL15520543 | 0.86 | RXRA (0.39) | RXRARXRBTRPM8CNR1CNR2 | |
| SCHEMBL12096941 | 0.83 | PPARG (0.52) | ACLYPPARGPPARD | |
| SCHEMBL15519840 | 0.83 | CNR1 (0.39) | RXRARXRBTRPM8CNR1CNR2 | |
| SCHEMBL2362775 | 0.83 | RORC (0.39) | RXRARXRBRORCACLYPPARG | |
| SCHEMBL14054088 | 0.83 | NOD1 (0.40) | PPARGPPARDPSEN1PSEN2APH1B | |
| SCHEMBL14053826 | 0.83 | MRGPRX4 (0.35) | CNR1CNR2PPARGPPARDNOD1 | |
| SCHEMBL14124725 | 0.81 | NOD1 (0.40) | PPARGPPARDNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2521727-B1 | NEW BENZOIC PYRROLOPYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PARKINSON'S DISEASE | INVENTIVA (FR) | 2014-03-19 | — | — | EP | claimed |
| US-8546385-B2 | Benzoic pyrrolopyridine derivatives | LABORATOIRES FOURNIER SA (FR) | 2013-10-01 | — | — | US | claimed |
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | LABORATOIRES FOURNIER SA (FR) | 2012-11-29 | — | — | US | claimed |
| EP-2521727-A1 | NOVEL BENZOIC PYRROLOPYRIDINE DERIVATIVES | Laboratoires Fournier S.A. (FR) | 2012-11-14 | — | — | EP | claimed |
| WO-2011083278-A1 | NOVEL BENZOIC PYRROLOPYRIDINE DERIVATIVES | LABORATOIRES FOURNIER SA (FR) | 2011-07-14 | — | — | WO | claimed |
| EP-2521727-B1 | NEW BENZOIC PYRROLOPYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PARKINSON'S DISEASE | INVENTIVA (FR) | 2014-03-19 | — | — | EP | disclosed |
| US-8546385-B2 | Benzoic pyrrolopyridine derivatives | LABORATOIRES FOURNIER SA (FR) | 2013-10-01 | — | — | US | disclosed |
| US-8546385-B2 | Benzoic pyrrolopyridine derivatives | LABORATOIRES FOURNIER SA (FR) | 2013-10-01 | — | — | US | disclosed |
| US-8546385-B2 | Benzoic pyrrolopyridine derivatives | LABORATOIRES FOURNIER SA (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | LABORATOIRES FOURNIER SA (FR) | 2012-11-29 | — | — | US | disclosed |
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | LABORATOIRES FOURNIER SA (FR) | 2012-11-29 | — | — | US | disclosed |
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | LABORATOIRES FOURNIER SA (FR) | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302560-A1 | Novel Benzoic Pyrrolopyridine Derivatives | NCOR1, NCOR2, NR0B1 | RXRA 82/4885RXRB 62/4885TRPM8 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.